Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after 177Lu-octreotate

Endocrine-Related Cancer

Volumn 20, Issue 6, 2013, Pages 825-831

  Kamp, Kimberly ^a   Gumz, Brenda ^b   Feelders, Richard A ^a   Kwekkeboom, Dik J ^a   Kaltsas, Gregory ^c   Costa, Frederico P ^b   De Herder, Wouter W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Cardiology   (Brazil)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Everolimus; Gep; Multicenter; Neuroendocrine tumor; Post 177Lu tate; Safety

Indexed keywords

ALANINE AMINOTRANSFERASE; EVEROLIMUS; OCTREOTATE LU 177; OCTREOTIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; DYSGEUSIA; EPISTAXIS; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; INFECTION; KIDNEY FAILURE; LEUKOPENIA; MALE; MIDDLE AGED; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROENDOCRINE TUMOR; PERIPHERAL EDEMA; PRURITUS; RASH; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EVEROLIMUS; GEP; MULTICENTER; NEUROENDOCRINE TUMOR; POST-177LU-TATE; SAFETY;

ADULT; AGED; BONE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL NEOPLASMS; LIVER NEOPLASMS; LUTETIUM; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; OCTREOTIDE; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SAFETY; SIROLIMUS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84891405002     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0254     Document Type: Article

References (13)

1. Bergsma H, van Vliet EI, Teunissen JJ, Kam BL, de Herder WW, Peeters RP, Krenning EP & Kwekkeboom DJ 2012 Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Best Practice & Research. Clinical Gastroenterology 26 867-881. (doi:10.1016/j.bpg.2013.01.004)
2. van Essen M, Krenning EP, Kam BL, de Herder WW, Feelders RA & Kwekkeboom DJ 2010 Salvage therapy with 177Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. Journal of Nuclear Medicine 51 383-390. (doi:10.2967/jnumed.109. 068957)
3. Fraenkel M, Kim MK, Faggiano A & Valk GD 2012 Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Practice & Research. Clinical Gastroenterology 26 691-703. (doi:10.1016/j.bpg.2013.01.006)
4. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO & Krenning EP 2008 Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. Journal of Clinical Oncology 26 2124-2130. (doi:10.1200/JCO.2007.15. 2553)
5. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP et al. 2008 Gastroenteropancreatic neuroendocrine tumours. Lancet Oncology 9 61-72. (doi:10.1016/S1470-2045(07) 70410-2)
6. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM et al. 2011 Everolimus plus octreotide long-Acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378 2005-2012. (doi:10.1016/S0140- 6736(11)61742-X)
7. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Eriksson B, Falchetti A, FalconiM & Komminoth P 2006 TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 449 395-401. (doi:10.1007/s00428- 006-0250-1)
8. Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A et al. 2007 TNM staging of midgut and (hind)gut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 451 757-762. (doi:10. 1007/s00428-007-0452-1)
9. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M et al. 2009 Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology 27 4656-4663. (doi:10.1200/ JCO.2009.22.8510)
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 92 205-216. (doi:10.1093/jnci/92.3.205)
11. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A et al. 2008 Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. Journal of Clinical Oncology 26 4311-4328. (doi:10.1200/JCO.2008.16.7858)
12. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D et al. 2010 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. Journal of Clinical Oncology 28 69-76. (doi:10.1200/JCO.2009.24.2669)
13. Yao JC, Shah MH, Ito T, Lombard-Bohas C, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG et al. 2011 Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine 364 514-523. (doi:10.1056/NEJMoa1009290)